South San Francisco, United States
Vilya, founded in 2022, is a pioneering entity in the Biotechnology and Pharmaceutical sectors, headquartered in the United States. Operating under the slogan "Compute Beyond Nature," the company is transforming how new medicines are developed by venturing into unexplored chemical realms.
Co-founded by a team from the Institute of Protein Design under the guidance of David Baker, Ph.D., and supported by ARCH Venture Partners, Vilya leverages advanced computational techniques to design molecular structures not found in nature. Their goal is to create a novel class of medicines that can precisely target disease biology, thereby offering new avenues for curing diseases.
The company's credibility and potential have been reinforced by a significant $21.00M Series A investment, closed on June 1, 2024. This funding round was backed by notable ventures including Madrona, ARCH Venture Partners, Menlo Ventures, Altitude Life Sciences, LifeForce Capital, and nVentures.
